Arslan Umut, Arslan Deniz, Özmert Emin
Bioretina Eye Clinic, Ankara University Technopolis, Ankara, Turkey.
Department of Ophthalmology, Ankara University Faculty of Medicine, Ankara, Turkey.
Case Rep Ophthalmol. 2025 Feb 27;16(1):221-231. doi: 10.1159/000544755. eCollection 2025 Jan-Dec.
Vitreous, retinal, and suprochoroidal hemorrhages might develop secondary to trauma, retinal tear or detachment, neovascularization due to ischemic retina. If the clearance of retinal and vitreous hemorrhages can be accelerated, more effective treatments can be planned for the underlying pathology.
We present 6 different cases with dense vitreous, preretinal, and subretinal hemorrhages due to Valsalva retinopathy, polypoid choroidal vasculopathy, diabetic retinopathy, neovascular age-related macular degeneration, retinitis pigmentosa with vasculitis, and myopic choroidal neovascularization. To accelerate the clearance of these dense intraocular hemorrhages, a novel nonsurgical method of electromagnetic iontophoresis (MagnoVision™) was used together with some appropriate medications in an outpatient setting without any complications or side effects. In all cases, liquefaction of the intraocular hemorrhage began by 5 days and mostly resolved by 10 days. This nonsurgical rapid clearance allowed us to diagnose and evaluate the underlying retinal and choroidal pathologies earlier and to treat them appropriately as early as possible.
Combined use of electromagnetic iontophoresis, subtenon platelet-rich plasma and bevacizumab injection, and oral bromelain can be considered as an effective and safe new treatment method for vitreous and retinal hemorrhages without any need for surgical intervention.
玻璃体、视网膜及脉络膜上腔出血可能继发于外伤、视网膜裂孔或脱离、缺血性视网膜所致的新生血管形成。如果能加速视网膜和玻璃体出血的清除,就能针对潜在病变制定更有效的治疗方案。
我们呈现了6例不同病因导致的玻璃体积血、视网膜前出血和视网膜下出血病例,病因分别为瓦尔萨尔瓦视网膜病变、息肉样脉络膜血管病变、糖尿病视网膜病变、新生血管性年龄相关性黄斑变性、伴有血管炎的色素性视网膜炎以及近视性脉络膜新生血管形成。为加速这些严重眼内出血的清除,在门诊环境中采用了一种新型非手术方法——电磁离子导入法(MagnoVision™),并联合使用了一些适当的药物,未出现任何并发症或副作用。在所有病例中,眼内出血在5天内开始液化,大多在10天内消退。这种非手术快速清除使我们能够更早地诊断和评估潜在的视网膜和脉络膜病变,并尽早进行适当治疗。
电磁离子导入法、球周注射富含血小板血浆和贝伐单抗以及口服菠萝蛋白酶联合使用,可被视为一种有效且安全的治疗玻璃体和视网膜出血的新方法,无需任何手术干预。